Advanced search
Publication Cover
Journal of Hepatocellular Carcinoma Volume 9, 2022 - Issue
Submit an article Journal homepage
97
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab

Muhammad O Awiwi1 Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0001-9814-4229View further author information
ORCID Icon,
Khaled M Elsayes1 Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0184-0717View further author information
ORCID Icon,
Yehia I Mohamed2 Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-5192-3804View further author information
ORCID Icon,
Lina Altameemi2 Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Migena Gjoni3 Department of Internal Medicine, The of Istanbul-Cerrahpasa Hospital, Istanbul, TurkeyView further author information
,
Omayr Muhammad Irshad4 John Sealy School of Medicine, Galveston, TX, USAORCID Iconhttps://orcid.org/0000-0003-1058-3265View further author information
ORCID Icon,
Ahmed Sayed Ahmed5 Department of Gastroenterology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0001-9994-6303View further author information
ORCID Icon,
Ahmad O Kaseb2 Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
&
Usama Salem1 Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
 show all
Pages 913-927 | Received 27 Jun 2022, Accepted 24 Aug 2022, Published online: 30 Aug 2022

References

  • Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2
  • Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
  • Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic Therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38(36):4317–4345. doi:10.1200/JCO.20.02672
  • Vogel A, Martinelli E. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines. Ann Oncol. 2021;32(6):801–805. doi:10.1016/j.annonc.2021.02.014
  • Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
  • Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-1247132
  • Wang JH, Chen YY, Kee KM, et al. The prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab. Cancers. 2022;14(2). doi:10.3390/cancers14020343.
  • Öcal O, Ingrisch M, Ümütlü MR, et al. Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma. Br J Cancer. 2022;126(2):211–218. doi:10.1038/s41416-021-01577-6
  • Marasco G, Colecchia A, Bacchi Reggiani ML, et al. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: a multicenter study. Dig Liver Dis. 2021;53(8):1011–1019. doi:10.1016/j.dld.2020.12.001
  • Kim BK, Kim KA, An C, et al. Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. Liver Int. 2015;35(6):1722–1730. doi:10.1111/liv.12751
  • Marasco G, Poggioli F, Colecchia A, et al. A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: a multicenter study. Cancers. 2021;13(11):2677. doi:10.3390/cancers13112677
  • Mansour D, McPherson S. Management of decompensated cirrhosis. Clin Med. 2018;18(Suppl 2):s60–s65. doi:10.7861/clinmedicine.18-2-s60
  • Hung TH, Tseng CW, Tsai CC, Tsai CC, Tseng KC, Hsieh YH. The long-term outcomes of cirrhotic patients with pleural effusion. Saudi J Gastroenterol. 2018;24(1):46–51. doi:10.4103/sjg.SJG_336_17
  • Khan AR, Wei X, Xu X. Portal vein tumor thrombosis and hepatocellular carcinoma - The changing tides. J Hepatocell Carcinoma. 2021;8:1089–1115. doi:10.2147/JHC.S318070
  • Guarino M, Cucchetti A, Pontillo G, et al. Pattern of macrovascular invasion in hepatocellular carcinoma. Eur J Clin Invest. 2021;51(7):e13542. doi:10.1111/eci.13542
  • Ikai I, Arii S, Okazaki M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37(9):676–691. doi:10.1111/j.1872-034X.2007.00119.x
  • Kokudo T, Hasegawa K, Yamamoto S, et al. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. J Hepatol. 2014;61(3):583–588. doi:10.1016/j.jhep.2014.04.032
  • Zhang ZY, Zhang EL, Zhang BX, Chen XP, Zhang W. Treatment for hepatocellular carcinoma with tumor thrombosis in the hepatic vein or inferior vena cava: a comprehensive review. World J Gastrointest Surg. 2021;13(8):796–805. doi:10.4240/wjgs.v13.i8.796
  • Lee JH, Lee JM, Kim SJ, et al. Enhancement patterns of hepatocellular carcinomas on multiphasic multidetector row CT: comparison with pathological differentiation. Br J Radiol. 2012;85(1017):e573–583. doi:10.1259/bjr/86767895
  • Koulakian H, Allaham W, Vilgrain V, Ronot M. Non-measurable infiltrative HCC: is post-contrast attenuation on CT a sign of tumor response? Eur Radiol. 2019;29(8):4389–4399. doi:10.1007/s00330-018-5805-4
  • Katagiri S, Yamamoto M. Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus. Surg Today. 2014;44(2):219–226. doi:10.1007/s00595-013-0585-6
  • Cheng S, Yang J, Shen F, et al. Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern hepatobiliary surgical hospital consensus statement. Oncotarget. 2016;7(26):40816–40829. doi:10.18632/oncotarget.8386

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.